Search results for " Infectious"

showing 10 items of 271 documents

Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

2017

Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014). Methods: The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely t…

Alcoholic liver diseasePathologyCirrhosisliver diseasesHepatocellular carcinomaPrevalenceChronic liver diseaseGastroenterology0302 clinical medicinecohort studiesEpidemiologymiddle aged030212 general & internal medicinehumansChronic liver diseasesHBV infectionChronic hepatitisadultChronic liver diseaseGeneral MedicineHepatitis CHepatitis BHCV infectionagedInfectious DiseasesItalyyoung adult030211 gastroenterology & hepatologyCohort studyMicrobiology (medical)medicine.medical_specialtyprevalence03 medical and health sciencesInternal medicinemedicineLiver Diseases AlcoholicAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinoma; Microbiology (medical); Infectious DiseasesAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinomabusiness.industryAlcoholic liver diseaseAlcoholic liver diseasesmedicine.diseaseprospective studiessex factorsChronic hepatitihepatitis Bhepatitis Cbusinesschronic diseasealcoholic liver diseases; chronic hepatitis; chronic liver diseases; HBV infection; HCV infection; hepatocellular carcinoma; adult; aged; chronic disease; cohort studies; hepatitis B; hepatitis C; humans; Italy; liver diseases; liver diseases alcoholic; middle aged; prevalence; prospective studies; sex factors; young adultalcoholic
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct

Developments in pediatrics in 2020: choices in allergy, autoinflammatory disorders, critical care, endocrinology, genetics, infectious diseases, micr…

2021

AbstractIn this article, we describe the advances in the field of pediatrics that have been published in the Italian Journal of Pediatrics in 2020. We report progresses in understanding allergy, autoinflammatory disorders, critical care, endocrinology, genetics, infectious diseases, microbiota, neonatology, neurology, nutrition, orthopedics, respiratory tract illnesses, rheumatology in childhood.

Allergyrespiratory tract illnessesRespiratory Tract DiseasesrheumatologyChild Nutrition SciencesReviewinfectious diseasesPediatricsneonatologyRJ1-570endocrinologyRare DiseasesHypersensitivitymicrobiotaortopedicsHumansgeneticsInfectious Disease MedicineAllergy Autoinflammatory disorders Child Nutrition Sciences COVID-19 Critical care Endocrinology Gastrointestinal Microbiome Genetics Hypersensitivity Infectious Disease Medicine Infectious diseases Microbiota Neonatology Neurology Nutrition Orthopedics Rare Diseases Respiratory Tract Diseases RheumatologyneurologyCOVID-19General MedicineGastrointestinal Microbiomecritical careOrthopedicsnutritionautoinflammatory disordersItalian Journal of Pediatrics
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct

Biomedical Applications of Polylactide (PLA) and Its Copolymers.

2018

n/a

Anti-Infective AgentPolyestersMicrofluidicsPolyesterPharmaceutical ScienceBiocompatible Materials02 engineering and technology01 natural sciencesAnalytical ChemistryPolymerizationlcsh:QD241-441Nanoparticlelcsh:Organic chemistryAnti-Infective AgentsDrug DiscoveryCopolymerHumansPhysical and Theoretical ChemistryDrug CarrierBiocompatible MaterialDrug CarriersPolymer scienceTissue Scaffolds010405 organic chemistryChemistryOrganic Chemistry021001 nanoscience & nanotechnologyBone Diseases Infectious0104 chemical sciencesBone Diseases Infectioun/aEditorialMicrofluidicChemistry (miscellaneous)PeptideMolecular MedicineNanoparticles0210 nano-technologyPeptidesHumanMolecules (Basel, Switzerland)
researchProduct

Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Af…

2021

Background: In this cross-sectional, international study, we aimed to analyze vector-borne and zoonotic infections (VBZI), which are significant global threats. Method: VBZIs’ data between May 20–28, 2018 was collected. The 24 Participatingcountries were classified as lower-middle, upper-middle, and high-income. Results: 382 patients were included. 175(45.8%) were hospitalized, most commonly in Croatia, Egypt, and Romania(P = 0.001). There was a significant difference between distributions of VBZIs according to geographical regions(P < 0.001). Amebiasis, Ancylostomiasis, Blastocystosis, Cryptosporidiosis, Giardiasis, Toxoplasmosis were significantly more common in the Middle-East while B…

AsiaSurveillance data030231 tropical medicineeducationEconomic statuTickSocioeconomic FactorZoonosis03 medical and health sciences0302 clinical medicineEconomic statusZoonosiMultidisciplinary approachZoonosesEnvironmental healthmedicineAnimalsHumansHemorrhagic Fever Crimean ...economic status ; infection ; tick ; vector ; zoonosisSocioeconomic statushealth care economics and organizationsCross-Sectional Studie0303 health sciencesZoonotic InfectionbiologyAnimal030306 microbiologyZoonosisSignificant differencePublic Health Environmental and Occupational HealthAn ID-IRI survey in 24 countries of Europe Africa and Asia- TRAVEL MEDICINE AND INFECTIOUS DISEASE cilt.44 2021 [Saydam F. N. Erdem H. ANKARALI H. Ramadan M. E. E. El-Sayed N. M. Civljak R. Pshenichnaya N. Moroti R. V. Mahmuodabad F. M. Maduka A. V. et al. -Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses]medicine.diseasebiology.organism_classification3. Good healthEuropeCross-Sectional StudiesInfectious DiseasesGeographySocioeconomic FactorsVector (epidemiology)AfricaHemorrhagic Fever Virus Crimean-CongoHemorrhagic Fever CrimeanVectorInfectionTick
researchProduct

Nuove varianti di Bronchite Infettiva negli allevamenti avicoli siciliani

2013

Avian Infectious Bronchitis (IB) is a disease caused by a Coronavirus, included in Coronaviridae family. The disease, endemic in Italy, affects both broilers and laying hens. It represents one of the main health issue in sicilian poultry farms. The presence of new antigenic variants makes problematic the implementation of an adequate prophylaxis through the use of appropriate vaccines. The present work aims to study the spread of IB strains in Sicily by serological and biomolecular tests in order to investigate the presence of "historical" strains as well as new strains and to carry out the genotyping of viruses isolated. The serological results show that the used vaccination protocols are …

Avian Infectious Bronchitis QX strain broilers
researchProduct

Invasion Ability and Disease Dynamics of Environmentally Growing Opportunistic Pathogens under Outside-Host Competition

2014

Most theories of the evolution of virulence concentrate on obligatory host-pathogen relationship. Yet, many pathogens replicate in the environment outside-host where they compete with non-pathogenic forms. Thus, replication and competition in the outside-host environment may have profound influence on the evolution of virulence and disease dynamics. These environmentally growing opportunistic pathogens are also a logical step towards obligatory pathogenicity. Efficient treatment methods against these diseases, such as columnaris disease in fishes, are lacking because of their opportunist nature. We present a novel epidemiological model in which replication and competition in the outside-hos…

Bacterial Diseases0106 biological sciencesPopulation ModelingDisease01 natural sciencesTheoretical EcologyMedicine and Health SciencesPathogenPOPULATIONmedia_common0303 health scienceseducation.field_of_studyPREDATIONMultidisciplinaryEcologyTransmission (medicine)EcologySimulation and ModelingQRCHANNEL CATFISHEVOLUTIONARY DYNAMICSCOMMUNITYInfectious DiseasesHost-Pathogen Interactions1181 Ecology evolutionary biologyMedicineAlgorithmsResearch ArticleTRANSMISSIONSciencemedia_common.quotation_subjecteducationPopulationVirulenceOpportunistic InfectionsBiologyResearch and Analysis Methods010603 evolutionary biologyCompetition (biology)03 medical and health sciences14. Life underwaterParasite EvolutioneducationEvolutionary dynamicsta413030304 developmental biologyEvolutionary BiologyMathematical ModelingSTABILITYMORTALITYEcology and Environmental SciencesBiology and Life SciencesComputational BiologyFLAVOBACTERIUM-COLUMNAREOutbreakModels TheoreticalEmerging Infectious DiseasesEvolutionary Ecologyta1181VIRULENCEParasitologyInfectious Disease ModelingPLoS ONE
researchProduct

Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic se…

2017

We evaluated the performance of QuantiFERON-TB Gold Plus (QFT-Plus), which includes two Mycobacterium tuberculosis antigen formulations (TB1 and TB2), for detection of latent tuberculosis infection during pregnancy. Eight-hundred-twenty-nine Ethiopian pregnant women (5.9% HIV-positive) were tested with QFT-Plus, with bacteriological sputum analysis performed for women with clinically suspected tuberculosis and HIV-positive women irrespective of clinical presentation. QFT-Plus read-out was categorized according to the conventional cut-off (0.35 IU/ml) for both antigen formulations. In addition, we analysed the distribution of QFT-Plus results within a borderline zone (0.20–0.70 IU/ml), and i…

Bacterial DiseasesRNA virusesPhysiologyMaternal Healthlcsh:MedicineHIV InfectionsPathology and Laboratory MedicineGastroenterologyWhite Blood Cells0302 clinical medicineImmunodeficiency VirusesPregnancyAnimal CellsMedicine and Health SciencesCell Cycle and Cell Division030212 general & internal medicinePregnancy Complications InfectiousYoung adultlcsh:ScienceMultidisciplinarybiologyLatent tuberculosisT CellsObstetrics and GynecologyGestational ageActinobacteriaInfectious DiseasesMedical MicrobiologyCell ProcessesViral PathogensVirusesFemalePathogensCellular Typesmedicine.symptomResearch ArticleAdultmedicine.medical_specialtyTuberculosisImmune CellsImmunologyViral diseasesMicrobiologyMycobacterium tuberculosisInterferon-gammaYoung Adult03 medical and health sciencesAntigenLatent TuberculosisInternal medicineRetrovirusesmedicineHumansTuberculosisMicrobial PathogensSecretionPregnancyBlood CellsBacteriaTuberculin Testbusiness.industryLentiviruslcsh:ROrganismsHIVBiology and Life SciencesMycobacterium tuberculosisCell BiologyTropical Diseasesbiology.organism_classificationmedicine.disease030228 respiratory systemWomen's HealthSputumlcsh:QEthiopiaMitogensPhysiological ProcessesbusinessInterferon-gamma Release TestsPLOS ONE
researchProduct

Mammal assemblage composition predicts global patterns in emerging infectious disease risk

2021

Abstract As a source of emerging infectious diseases, wildlife assemblages (and related spatial patterns) must be quantitatively assessed to help identify high‐risk locations. Previous assessments have largely focussed on the distributions of individual species; however, transmission dynamics are expected to depend on assemblage composition. Moreover, disease–diversity relationships have mainly been studied in the context of species loss, but assemblage composition and disease risk (e.g. infection prevalence in wildlife assemblages) can change without extinction. Based on the predicted distributions and abundances of 4466 mammal species, we estimated global patterns of disease risk through …

BiodiversityDIVERSITYAnimal Sciences DeskzoonoositCommunicable Diseases EmergingeläinmaantiedetartuntatauditBureau DierwetenschappenPrimary Research ArticleGeneral Environmental ScienceBODY-SIZEMammals2. Zero hungerGlobal and Planetary ChangeEcologyEcologyassemblage composition; climate change; emerging infectious diseases; habitat loss; infectious disease hotspots; species distributionsassemblage compositionPOPULATION-DENSITYeliöyhteisötriskinarviointiPE&RCEXTINCTION RISKclimate changespecies distributions1181 Ecology evolutionary biologyEmerging infectious diseaseWILDLIFEhabitat lossWildlifeContext (language use)Biologyemerging infectious diseasesEVENNESSnisäkkäätAnimalsEnvironmental ChemistryeläimistöEcosystemPATHOGENSSPECIES DISTRIBUTION MODELS15. Life on landilmastonmuutoksetPrimary Research ArticlesbiodiversiteettiHabitat destruction13. Climate actionInfectious disease (medical specialty)villieläimetWildlife Ecology and ConservationSpatial ecologyBIODIVERSITYSpecies richnessLIVING FASTEnvironmental Sciencesinfectious disease hotspots
researchProduct